- Home
- EVT vs IMCR Comparison
EVT vs IMCR Comparison
Compare EVT & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVT
- IMCR
- Stock Information
- Founded
- EVT 2003
- IMCR 2008
- Country
- EVT United States
- IMCR United Kingdom
- Employees
- EVT N/A
- IMCR N/A
- Industry
- EVT Finance Companies
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EVT Finance
- IMCR Health Care
- Exchange
- EVT Nasdaq
- IMCR Nasdaq
- Market Cap
- EVT 1.8B
- IMCR 1.7B
- IPO Year
- EVT N/A
- IMCR 2021
- Fundamental
- Price
- EVT $24.60
- IMCR $29.40
- Analyst Decision
- EVT
- IMCR Buy
- Analyst Count
- EVT 0
- IMCR 13
- Target Price
- EVT N/A
- IMCR $65.18
- AVG Volume (30 Days)
- EVT 121.5K
- IMCR 246.4K
- Earning Date
- EVT 01-01-0001
- IMCR 11-06-2024
- Dividend Yield
- EVT 7.72%
- IMCR N/A
- EPS Growth
- EVT N/A
- IMCR N/A
- EPS
- EVT N/A
- IMCR N/A
- Revenue
- EVT N/A
- IMCR $296,312,000.00
- Revenue This Year
- EVT N/A
- IMCR $29.19
- Revenue Next Year
- EVT N/A
- IMCR $12.56
- P/E Ratio
- EVT N/A
- IMCR N/A
- Revenue Growth
- EVT N/A
- IMCR 25.09
- 52 Week Low
- EVT $18.70
- IMCR $28.17
- 52 Week High
- EVT $23.82
- IMCR $76.98
- Technical
- Relative Strength Index (RSI)
- EVT 36.30
- IMCR 35.14
- Support Level
- EVT $24.56
- IMCR $28.17
- Resistance Level
- EVT $25.62
- IMCR $29.91
- Average True Range (ATR)
- EVT 0.24
- IMCR 1.39
- MACD
- EVT -0.12
- IMCR -0.31
- Stochastic Oscillator
- EVT 7.52
- IMCR 23.81
About EVT Eaton Vance Tax Advantaged Dividend Income Fund of Beneficial Interest
EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND is a diversified, closed-end management investment company. Its objective is to provide a high level of after-tax total return consisting mainly of tax-advantaged dividend income and capital appreciation. The fund pursues its objective by investing in dividend-paying common and preferred stocks. Its portfolio of investments consists of electric utilities, energy equipment and services, food products, health care providers and services, internet software and services, and other areas.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.